Search Results - Al‐Ola Abdallah

  • Showing 1 - 17 results of 17
Refine Results
  1. 1
    Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years

    Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years by Varinder Kaur, Arjun Swami, Daisy Alapat, Al - Ola Abdallah, Pooja Motwani, Laura F. Hutchins, Yogesh Jethava

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy

    Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy by James A. Davis, Douglas W. Sborov, William Wesson, Kelley Julian, Al‐Ola Abdallah, Joseph P. McGuirk, Nausheen Ahmed, Hamza Hashmi

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

    Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma by James A. Davis, Danai Dima, Nausheen Ahmed, Shaun DeJarnette, Joseph P. McGuirk, Xuefei Jia, Shahzad Raza, Jack Khouri, Jason Valent, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access

    Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access by Nausheen Ahmed, Moazzam Shahzad, Ernie Shippey, Rajat Bansal, Muhammad Umair Mushtaq, Zahra Mahmoudjafari, Muhammad Salman Faisal, Marc Hoffmann, Al‐Ola Abdallah, Clint Divine, Mehdi Hamadani, Joseph P. McGuirk, Leyla Shune

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

    Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma by Danai Dima, James A. Davis, Nausheen Ahmed, Aishwarya Sannareddy, Hira Shaikh, Zahra Mahmoudjafari, Jack Khouri, Gurbakhash Kaur, Christopher Strouse, Jason Valent, Larry D. Anderson, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant

    Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant by Aytaj Mammadzadeh, Yara Shatnawi, Rawan Atallah, Benlazar Mohamed, Nihar Desai, Shahrukh K. Hashmi, Thiago Xavier Carneiro, Hira Shaikh, Christopher Strouse, Rakesh Popat, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al‐Ola Abdallah, Nausheen Ahmed

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the <scp>KarMMa</scp>‐1 trial eligibility criteria: A real‐world multicentre study

    Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the <scp>KarMMa</scp>‐1 trial eligibility criteria: A real‐world mul... by Danai Dima, Aliya Rashid, James A. Davis, Leyla Shune, Al‐Ola Abdallah, Hong Li, Shaun DeJarnette, Jack Khouri, Louis Williams, Hamza Hashmi, Shahzad Raza, Joseph P. McGuirk, Faiz Anwer, Nausheen Ahmed

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019

    Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019 by Nicole Baranda Balmaceda, Muhammad Aziz, Viveksandeep Thoguluva Chandrasekar, Brian McClune, Suman Kambhampati, Leyla Shune, Al-Ola Abdallah, Faiz Anwer, Aneela Majeed, Muzaffar H. Qazilbash, Siddhartha Ganguly, Joseph P. McGuirk, Ghulam Rehman Mohyuddin

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

    Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study by Paul G. Richardson, Hans C. Lee, Al-Ola Abdallah, Adam D. Cohen, Prashant Kapoor, Peter M. Voorhees, Axel Hoos, Karrie Wang, January Baron, Trisha Piontek, Julie Byrne, Scott Richmond, Roxanne C. Jewell, Joanna Opalinska, Ira Gupta, Sagar Lonial

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

    Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy by Danai Dima, Al‐Ola Abdallah, James A. Davis, Hussein Awada, Utkarsh Goel, Aliya Rashid, Shaun DeJarnette, Faiz Anwer, Leyla Shune, Shahzad Raza, Zahra Mahmoudjafari, Louis O. Williams, Beth Faiman, Joseph P. McGuirk, Craig S. Sauter, Nausheen Ahmed, Jack Khouri, Hamza Hashmi

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

    Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study by Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al‐Ola Abdallah, Natalie S. Callander, Douglas W. Sborov, Attaya Suvannasankha, Katja Weisel, Peter M. Voorhees, Lynsey Womersley, January Baron, Trisha Piontek, Eric Lewis, Joanna Opalińska, Ira Gupta, Adam D. Cohen

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma

    Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma by William Wesson, Danai Dima, Nahid Suleman, M Saif, Carine Tabak, Emerson Logan, James A. Davis, Mary McGann, Fateeha Furqan, Meera Mohan, Aliya Rashid, Al‐Ola Abdallah, Fauzia Ullah, Leyla Shune, Muhammad Umair Mushtaq, Shahzad Raza, Joseph P. McGuirk, Mehdi Hamadani, Faiz Anwer, Hamza Hashmi, Nausheen Ahmed

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Global Access to Multiple Myeloma Therapies

    Global Access to Multiple Myeloma Therapies by Rawan Atallah, Yara Shatnawi, MD Fathima Shehnaz Ayoobkhan, M Saif, Muhammad Naeem, Emerson Logan, Muhammad Umair Mushtaq, Shabeeha Rana, Aytaj Mammadzadeh, Shahrukh K. Hashmi, Benlazar Mohamed, Nihar Desai, Thiago Xavier Carneiro, Rakesh Popat, Joseph P. McGuirk, Shebli Atrash, Zahra Mahmoudjafari, Nada Hamad, Faiz Anwer, Nausheen Ahmed, Al‐Ola Abdallah

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study

    Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study by Alexander M. Lesokhin, Richard LeBlanc, Meletios Α. Dimopoulos, Marcelo Capra, Carmelo Carlo‐Stella, Lionel Karlin, Jean‐François Castilloux, Peter A. Forsberg, Gurdeep Parmar, Axel Tosikyan, Luděk Pour, Vincent Ribrag, Rossella Ribolla, Al‐Ola Abdallah, Nadia Le Roux, Liyan Dong, Helgi van de Velde, Laurent Mayrargue, Lucie Lépine, Sandrine Macé, Philippe Moreau

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial

    Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial by Ajay K. Nooka, Adam D. Cohen, Hans C. Lee, Ashraf Badros, Attaya Suvannasankha, Natalie S. Callander, Al‐Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward N. Libby, Maria Chaudhry, Malin Hultcrantz, K. Martin Kortüm, Rakesh Popat, Douglas W. Sborov, Shawn Hakim, Eric Lewis, Boris Gorsh, Bharat Bhushan, Astrid McKeown, Ira Gupta, Joanna Opalinska, Paul G. Richardson, Sagar Lonial

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

    Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myelom... by Nico Gagelmann, Danai Dima, Maximilian Merz, Hamza Hashmi, Nausheen Ahmed, Natalia Tovar, Aina Oliver‐Cáldes, Friedrich Stölzel, Kristin Rathje, Luise Fischer, Patrick Born, Lisa Schäfer, Anca‐Maria Albici, Natalie Schub, Shlomit Kfir‐Erenfeld, Miri Assayag, Nathalie Asherie, Gerald Wulf, Soraya Kharboutli, Fabian Müller, Leyla Shune, James A. Davis, Faiz Anwer, Vladan Vučinić, Uwe Platzbecker, Francis Ayuk, Nicolaus Kröger, Jack Khouri, Carmelo Gurnari, Joseph P. McGuirk, Polina Stepensky, Al‐Ola Abdallah, Carlos Fernández de Larrea

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

    Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy by Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel, Tobias A.W. Holderried, Roland Fenk, Fabian Müller, Natalia Tovar, Aina Oliver‐Cáldes, Kristin Rathje, James A. Davis, David Fandrei, Vladan Vučinić, Soraya Kharboutli, Ben‐Niklas Baermann, Francis Ayuk, Uwe Platzbecker, Anca‐Maria Albici, Nathalie Schub, Friederike Schmitz, Leyla Shune, Jack Khouri, Faiz Anwer, Shahzad Raza, Joseph P. McGuirk, Zahra Mahmoudjafari, Kimberly Green, Cyrus Khandanpour, Marcel Teichert, Barbara Jeker, Michèle J. Hoffmann, Nicolaus Kröger, Bastian von Tresckow, Carlos Fernández de Larrea, Thomas Pabst, Al‐Ola Abdallah, Nico Gagelmann

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: